Morphic Therapeutic Email Format
Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees
Morphic Therapeutic is a biotech company developing oral therapies that target integrin receptors, with potential to treat immunological, fibrotic, neoplastic and vascular diseases. The work aims to offer an oral modality in a field where many integrin treatments have been injectable, extending the reach of these therapies. Recent reporting notes that Morphic is building a preclinical pipeline of molecules for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer. The company is based in Waltham, Massachusetts, and operates within the pharmaceutical manufacturing sector, with leadership linked to the long-running study of integrins initiated in the 1980s by its scientific founder. Integrins have historically been a drug target, with several injectable therapies approved for conditions including multiple sclerosis, inflammatory bowel diseases (ulcerative colitis and Crohn's disease), plaque psoriasis, and cardiovascular issues related to acute coronary syndromes and interventions. Morphic is described as a smaller to mid-sized organization focused on translating integrin biology into oral therapeutics.
1-888-653-2347 
support@leadiq.com 
